Therapies for COVID-19-Related Persistent Olfactory Disorders: One of the Good Fruits of the Pandemic

Sven Saussez; Luigi Angelo Vaira; Giacomo De Riu; Jérome R Lechien

doi:10.3390/pathogens12010072

Therapies for COVID-19-Related Persistent Olfactory Disorders: One of the Good Fruits of the Pandemic

Pathogens. 2023 Jan 3;12(1):72. doi: 10.3390/pathogens12010072.

Authors

Sven Saussez¹, Luigi Angelo Vaira^{2

3}, Giacomo De Riu², Jérome R Lechien^{1

4}

Affiliations

¹ Department of Human and Experimental Oncology, Faculty of Medicine UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), B7000 Mons, Belgium.
² Maxillofacial Surgery Operative Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.
³ Biomedical Science Department, PhD School of Biomedical Science, University of Sassari, 07100 Sassari, Italy.
⁴ Department of Otolaryngology-Head Neck Surgery, Elsan Polyclinic of Poitiers, 86000 Poitiers, France.

Abstract

At the beginning of 2021, the scientific community realized the burden of COVID-19-related persistent olfactory disorders (ODs). The percentage of those infected with COVID-19 who developed severe and persistent ODs [1-3] with devastating effects on their quality of life was 5 to 40% [4,5].

Publication types

Editorial